How much funding has JW Therapeutics raised?

JW Therapeutics has raised $190.0M in total funding, most recently a Series B round.

Who are JW Therapeutics's investors?

JW Therapeutics's investors include CPE Capital, Mirae Asset, ARCH Venture Partners, WuXi AppTec, Temasek.

When was JW Therapeutics founded?

JW Therapeutics was founded in 2016.

Where is JW Therapeutics headquartered?

JW Therapeutics is headquartered in Shanghai, China.

What industry is JW Therapeutics in?

JW Therapeutics operates in Biotech, Healthcare.

How many employees does JW Therapeutics have?

JW Therapeutics has 201-500 employees.

JW Therapeutics

IPO

上海药明巨诺生物科技有限公司

Public · Shanghai, China · Founded 2016 · $190.0M raised

Biotech

Healthcare

Headquarters: Shanghai
Employees: 201–500
Founded: 2016
Business Model: B2B
Website: jwtherapeutics.com

Total Funding: $190.0M
Last Round: $100.0M Series BJun 2020
Rounds: 2
Type: Public

About

JW Therapeutics (HKEx: 2126) is an independent biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products in China and globally. Founded in 2016 and headquartered in Shanghai, the company's flagship product Carteyva® (relma-cel) is an approved anti-CD19 CAR-T therapy for relapsed/refractory large B-cell lymphoma. Its pipeline spans hematologic malignancies, solid tumors, and autoimmune diseases.

Summary

JW Therapeutics is a Biotech company based in Shanghai, China, founded in 2016. It has raised $190.0M in total across 2 rounds, most recently a $100.0M Series B round in Jun 2020. Investors include CPE Capital, Mirae Asset and ARCH Venture Partners.